Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F520 safety in advanced tumors
NCT03657381Phase 1Unknown
- Sponsor
- Shandong New Time Pharmaceutical
- Start
- Mar 2019
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of rulonilimab in solid tumor (advanced stage), lymphoma and Hodgkin lymphoma (HL) (11 arms), sponsored by Shandong New Time Pharmaceutical. Primary endpoint: Number of participants with treatment-related adverse events at 1.5 years. Status: unknown.
02
Drugs
rulonilimab
03
Conditions
solid tumor (advanced stage)lymphomaHodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT03657381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03657381.